Navigation Links
ASU researchers develop new device to help image key proteins at room temperature
Date:12/20/2013

TEMPE, Ariz. A group of researchers from Arizona State University are part of a larger team reporting a major advance in the study of human proteins that could open up new avenues for more effective drugs of the future. The work is being reported in this week's Science magazine.

In the paper, "Serial femtosecond crystallography of G-protein-coupled receptors," the team reports that they have been successful in imaging at room temperature the structure of G protein-coupled receptors (GPCR) with the use of an x-ray free-electron laser.

GPCR's are a highly diverse group of membrane proteins that mediate cellular communication. Because of their involvement in key physiological and sensory processes in humans, they are thought to be prominent drug targets.

The method described in the paper was applied for the first time to this important class of proteins, for which the 2012 Nobel Prize was awarded to Brian Kobilka and Robert Lefkowitz, said John Spence, an Arizona State University professor of physics. Spence also is the director of science at National Science Foundation's BioXFEL Science and Technology Center and a team member on the Science paper.

"These GPCR's are the targets of a majority of drug molecules," Spence said, but they are notoriously difficult to work with. This is the first time structural observations of the GPCR's have been made at room temperature, allowing researchers to overcome several disadvantages of previous imaging methods of the proteins.

"Normally, protein crystallography is performed on frozen samples, to reduce the effects of radiation damage," Spence said. "But this new work was based on an entirely new approach to protein crystallography, called SFX (Serial Femtosecond Crystallography) developed jointly by ASU, the Deutsches Elektronen-Synchrotron (DESY) and the SLAC National Accelerator Laboratory."

"This method uses brief pulses of x-rays instead of freezing the sample to avoid damage, and so it reveals the structure which actually occurs in a cell at room temperature, not the frozen structure," Spence added. "The 50 femtosecond pulses (120 per second) 'outrun' radiation damage, giving a clear picture of the structure before it is vaporized by the beam."

The femtosecond crystallography technique could enable researchers to view molecular dynamics at a time-scale never observed before. Spence said the method basically operates by collecting the scattering for the image so quickly that images are obtained before the sample is destroyed by the x-ray beam.

By 'outrunning' radiation-damage processes in this way, the researchers can record the time-evolution of molecular processes at room temperature, he said.

Spence said ASU played a crucial role in the project described in Science, through the invention by Uwe Weierstall (an ASU physics professor) of an entirely new device for sample delivery suited to this class of proteins.

The lipic cubic phase (LCP) injector that Weierstall developed replaces the continuous stream of liquid (which sends a continuously refreshed stream of proteins across the pulsed x-ray beam) with a slowly moving viscous stream of 'lipid cubic phase solution,' which has the consistency of automobile grease.

"We call it our 'toothpaste jet,'" Spence said.

He added that the LCP solves three problems associated with previous SFX work, and made this new work possible:

  • The viscosity slows the flow rate so the crystals emerge at about the same rate as the x-ray pulses come along, hence no protein is wasted. This is important for the study of human protein, which is more costly than diamond on a per gram basis.
  • The "hit rate" is very high. Nearly all x-ray pulses hit protein particles.
  • Most important, LCP is itself a growth medium for protein nanocrystals.

"A big problem with the SFX work we have been doing over the past four years is that people did not know how to make the required nanocrystals," Spence said. "Now it seems many can be grown in the LCP delivery medium itself."


'/>"/>

Contact: Skip Derra
skip.derra@asu.edu
480-965-4823
Arizona State University
Source:Eurekalert

Related biology news :

1. With sinus study, Saint Louis University researchers find that harmless members of microbiome spark immune reaction
2. New anti-HIV drug target identified by University of Minnesota researchers
3. MU researchers develop advanced 3-dimensional force microscope
4. Researchers explain why some wound infections become chronic
5. Stanford researchers take a step toward developing a universal flu vaccine
6. Researchers engineer a hybrid 5 times more effective in delivering genetic material into cells
7. New organization brings together top researchers to sequence genomes of invertebrates
8. Bonefish spawning behavior in the Bahamas surprises researchers, should aid conservation
9. Where water is limited, researchers determine how much water is enough
10. Researchers at Penn help develop a dynamic model of tissue failure
11. Leibniz Prizes 2014: DFG honors 11 outstanding researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
(Date:6/23/2016)... India , June 23, 2016 ... media market research report to its pharmaceuticals section ... profiles, product details and much more. ... spread across 151 pages, profiling 15 companies and ... available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
(Date:6/22/2016)... , June 22, 2016   StockNewsNow.com , ... Video Interview with Dr. Nader Pourhassan , President ... company focused on the clinical development and potential commercialization ... of HIV infection, according to the company,s website (see ... on Tuesday, June 7 th , 2016, at the ...
Breaking Biology Technology: